The effect of biofeedback therapy in psychiatric rehabilitatio
Not Applicable
Completed
- Conditions
- SchizophreniaMental and Behavioural Disorders
- Registration Number
- ISRCTN78612833
- Lead Sponsor
- Medical University of Lublin
- Brief Summary
2021 Results article in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380506/ (added 12/04/2022) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/35741653/ (added 14/06/2023) 2022 Results article in https://pubmed.ncbi.nlm.nih.gov/36142912/ (added 14/06/2023)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 62
Inclusion Criteria
1. Patients diagnosed with schizophrenia (DSM-5), residual, in partial remission for =1.5 years
2. Patient’s consent
3. Aged 18-65 years
4. Right-handedness
Exclusion Criteria
1. Current neurological diseases
2. Mental disability
3. Alcohol or psychoactive substances addiction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measured at the beginning of the study and after 3 months:<br>1. Psychopathological symptoms measured using the Positive and Negative Syndrome Scale (PANSS)<br>2. Cognitive and psychosocial performance measured using the Beck Cognitive Insight Scale (BCIS), Color Trails Test (CTT)-1, CTT-2, d2, Acceptance of Illness Scale (AIS) and General Self-efficacy Scale (GSES)<br>3. Biochemical markers e.g. serum level of brain-derived neurotrophic factor (BDNF)<br>4. Event-related potentials (ERP) and quantitative electroencephalography – neurofeedback-dependent (QEEG-NF)
- Secondary Outcome Measures
Name Time Method There are no secondary outcome measures